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DNA is one of the most important components for all living organisms and many species, 
including humans, use DNA to store and transmit genetic information to new generations. 
Recent advances in the handling of DNA have made it possible to use DNA as a building 
block of nano-sized materials with precisely designed architectures. Although various 
approaches have been proposed to obtain DNA assemblies with designed architecture in the 
nano- to micrometer range, there is little information about their interaction with biological 
components, including target molecules. Understanding the interaction between DNA 
assemblies and the body is highly important for successful pharmaceutical and biomedical 
applications. Here, we first review the basic aspects of externally administered DNA 
molecules, including the stability, permeability and delivery issues. Then, we discuss the 
unique responses observed in the interaction of structured DNA assemblies and cells 
expressing Toll-like receptor-9, the receptor responsible for the recognition of unmethylated 
CpG dinucleotides that are abundant in the DNA of invading pathogens, such as bacteria and 
viruses. 
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1. Introduction 
DNA is one of the most important components of all living organisms. Genomic DNA is the 
archive of genetic information, which is the most important information for many species 
including humans, even though the sequence has always been continuously changing. This 
instability in terms of over millions of years has been changing the organisms, and some of 
those changes have allowed them to adapt to new environments and some others have resulted 
in their disappearance. For example, humans, other primates and guinea pigs have lost the 
ability to produce ascorbic acid, or vitamin C [1], even though they require the vitamin for 
healthy living. Genetic mutations sometimes cause diseases, even when only one base is 
deleted, or replaced by a different base if the change is critical to the expression of a 
functional protein at a normal level [2-5]. Most of mutations in genomic DNA are corrected 
by enzymatic systems to keep the information unchanged [6,7]. The double stranded structure 
of DNA makes this correction process precise, because the strand without mutations is used as 
a template for the correction. 
 From the structural point of view, there are many advantages in using DNA as a 
building block of nano-sized materials with precisely designed architecture [8-13]. In 
particular, the specificity of the hydrogen interactions between adenine-thymine and 
guanine-cytosine allows us to design the whole structure of DNA-based materials. In addition, 
two strands of double-stranded DNA can be covalently bound to each other using DNA ligase 
when the 5‟-end of one strand is complimentary to the 3‟-end of another strand. Oligomers or 
polymers of DNA can be chemically synthesized by automated machines in a large quantities, 
so that DNA with a proper length and sequence can be obtained with high purity in amounts 
required for clinical application. Under conditions where there are no enzymes degrading 
DNA, DNA is very stable compared with proteins, another component candidate for 
nano-sized materials with designed architecture. Restriction enzymes, ligases and other 
enzymes are available to design and modify the properties of DNA-based materials. 
 Recent advances in the development of DNA assemblies have greatly increased the 
possibility of using DNA as a building block of nano-sized systems for pharmaceutical and 
biomedical applications. Various methods have been proposed and unique structures, most of 
which could not be imagined a few years ago, have been successfully developed [14-22]. In 
general, such systems use the property of DNA to hybridize its complimentary sequence. Any 
structure can be prepared if one can imagine it, in a nano- to micro-scale. Figure 1 shows 
some examples of DNA assemblies, the generation of which has been confirmed in these 
previous studies. These uniquely structured DNA assemblies rarely exist in nature, so that it is 
not clear how they are recognized by living organisms. On the other hand, they are composed 
of natural DNA, so that they could be handled in the same fashion as those of natural origin. 
Thus, it is very important to understand how DNA assemblies are recognized by the body in 
order to develop DNA-based nano-sized systems for pharmaceutical and biomedical use. In 
this review, we summarize the basic characteristics of DNA molecules, such as their stability, 
membrane permeability and tissue distribution properties, and discuss the use of DNA-based 
nano-sized systems for pharmaceutical and biomedical applications. 
 
2. General requirements of DNA molecules for their pharmaceutical and biomedical 
application 
To exhibit biological functions, the externally administered DNA should reach the site of 
action in a biologically active form, as required for other pharmaceutical compounds. 
Generally speaking, there are two major hurdles in such applications of DNA molecules: one 
is biological instability and the other is poor ability to pass through biological membranes. 
Even though DNA is chemically stable compared with proteins, it is easily degraded within 
the body. Biological fluids, such as serum and extracellular fluid, and the cytosolic 
compartment contain DNases, DNA degrading enzymes [23]. Therefore, once recognized by 
these enzymes, DNA administered as a pharmaceutical agent will be degraded and no 
therapeutic benefits will be obtained. 
 DNA interacts with its target molecule once it reaches its site of action. If a DNA 
molecule is designed to interact with complementary DNA or RNA, the length of the DNA 
should be 15 nucleotides or longer to guarantee the specificity of binding to the target 
molecule [24]. This size limitation is determined by the size of the human genome. In addition, 
this length is also required to give the DNA a melting temperature high enough to form a 
stable duplex within cells under physiological conditions. However, these requirements are 
dependent on the type of nucleic acids. 
 An exception of DNA-based drugs is CpG DNA, an immunostimulatory compound, 
which exhibits its biological activity through the interaction with Toll-like receptor 9 (TLR9) 
[25]. TLR9 is localized in the endoplasmic reticulum and the endosomal/lysosomal 
compartments. Therefore, endocytic uptake, a major route for cellular uptake of 
macromolecules including DNA molecules, can sort CpG DNA to the subcellular 
compartments where TLR9 is localized. In this case, the membrane permeability does not 
prevent DNA from exhibiting its biological activity, and DNA as long as several thousand 




The problem of the biological instability of short strand of DNA, or oligodeoxynucleotide 
(ODN), has often been solved by chemical modification. Various forms of chemically 
modified ODN have been developed, includig phosphorothioate ODN, 2‟-O-methyl ODN, 
morpholino ODN, methylphosphonate, phosphoramidate ODN and locked nucleic acid 
(Figure 2) [27-30]. Peptide nucleic acids (PNA), which are not DNA or RNA but can 
hybridize with a complementary DNA/RNA, have also been developed [31]. The binding 
affinity of PNA to complementary nucleic acids is much greater than DNA or RNA of the 
same sequence because of the absence of the negative charge in the PNA strand. Covalent 
linkage of other molecules, such as cholesterol, has been found to be another approach to 
increasing the stability of ODN [32,33]. These chemically modified ODNs are more stable 
than the natural phosphodiester ODN, because the recognition and cleavage by nucleases is at 
least partly impaired by such modifications. 
 Attention should be paid to these modifications, because some of them, if not all, can 
alter the specificity of ODN to interact with target molecules. In addition, the physiochemical 
characteristics of ODN will be greatly changed by these modifications which, in turn, affect 
their pharmacokinetic profile after in vivo administration. For instance, phosphorothioate 
ODN is extensively bound to proteins compared with phosphodiester ODN [34]. This change 
in the interaction with biological components can be advantageous for an increase in the 
biological half-life of ODN but, at the same time, it could be a cause of tissue damage when 
chemically modified ODN is extensively bound to the cell surface. The stable nature of 




Another problem, that of „poor permeability‟, is difficult to solve, because it is closely related 
to the physicochemical nature of DNA/ODN. The monomer of DNA is a nucleotide, which is 
composed of 2‟-deoxyribose, one of the nitrogenous bases, i.e., adenine, thymine, guanine or 
cytosine, and phosphoric acid. The average molecular mass of nucleotides in DNA is about 
310. Considering that one of the smallest DNA molecules used as a pharmaceutical agent is 
single stranded and 15 bases in length, such small DNA molecules have a molecular weight of 
almost 5,000. Because of this size, DNA cannot easily pass through biological membranes. 
Furthermore, the large size of the DNA greatly limits the diffusion in the extracellular space 
and extravasation in tissues with a continuous endothelium [35-37]. In addition, the 
phosphoric acid gives the DNA a high negative charge. Since the cell surface is negatively 
charged because of the presence of negatively charged glycoproteins and glycolipids, the 
resulting electrical repulsion reduces the interaction of DNA with cells. 
 
2.3. Delivery issues 
In most cases, DNA should be delivered to the cytosol or the nucleus of cells of interest, 
where target molecules, such as DNA, RNA or proteins, exist. However, the large size and 
negative charge greatly restricts the entry of DNA into such subcellular compartments. 
Therefore, delivery systems should be considered in pharmaceutical applications to increase 
the intracellular delivery of such DNA molecules [38-42]. A simple and reliable delivery 
method is direct tissue injection of DNA [43-46]. This administration method is not limited to 
short DNA molecules, such as antisense ODN, but can be applied to huge plasmid DNA with 
a few thousand base pairs or more. The mechanism of the intracellular delivery of this method 
has not yet been fully elucidated, but damage to the membrane caused by the insertion of the 
needle and increased pressure due to the injection of solution into the extracellular spaces are 
believed to be involved in the intracellular delivery of DNA [47]. This mode of delivery is 
efficient, but a major drawback is the limited distribution of cells taking up DNA. A study on 
gene delivery reported that only cells located 5-10 mm from the injection site expressed the 
transgene after intramuscular injection of naked plasmid DNA [48,49]. However, this method 
can be effective when the number of target cells is small and they are located within a limited 
area. This is the case for age-related macular degeneration, in which some nucleic acid drugs, 
such as antisense ODN, are directly injected into the vitrea [50-52]. Iontophoresis or 
electroporation can be used to increase the delivery of DNA and other charged molecules, 
which can be topically applied or injected into tissues [53-55]. 
 For increased stability and effective delivery to the target site, DNA has been 
incorporated into particulate carriers, such as liposomes and micro-/nanospheres [56,57]. 
Incorporation of DNA into these particulates avoids the interaction of DNA with degrading 
enzymes, so that the stability of DNA is generally increased. Complex formation of DNA with 
cationic compounds, including cationic lipids, liposomes, and polymers, is another approach 
to increase the stability and delivery to the target site. Addition of these compounds to DNA 
generally results in the formation of complexes through an electrostatic interaction, and the 
surface of such complexes is positively charged. Then, these positively charged complexes 
can bind to the surface of cells, and eventually be internalized. Even though DNA is 
internalized, release from intracellular vesicles, such as endosomes and lysosomes, is required 
to reach the target DNA, RNA or proteins. Gene transfer studies have shown that the cytosolic 
delivery of DNA can be greatly increased by the use of molecules that disrupt or destroy the 
biological membranes [58-63]. 
 
3. DNA-based pharmaceuticals 
Because of its fundamental roles in biological activities, DNA has been considered for use as 
a pharmaceutical agent to treat a variety of diseases. An important application of DNA to 
treating human diseases is in the field of gene therapy, where an inherent or acquired disease 
is treated by correcting the function of the mutated genes or by supplementing therapeutic 
genes [64,65]. Plasmid DNA, double stranded DNA amplified by polymerase chain reaction, 
DNA complexed with lipids, liposomes or polymers, and a variety of viruses, including 
adenovirus, adeno-associated virus, retrovirus and lentivirus, have been used to deliver the 
gene of interest to target cells, and many clinical trials have been conducted worldwide. As 
described above, DNA can carry the information for proteins, so that a successful delivery of 
DNA results in the expression of therapeutic proteins in cells reached by the DNA. In addition, 
RNA transcribed from DNA is another class of pharmaceutical agents, because RNA, 
especially those with a unique structure, i.e., about 21-23 nucleotide sense and antisense 
strands with 2 nucleotide overhangs at both 3‟ ends, so-called small interfering RNA (siRNA), 
are one of the most potent compounds to inhibit gene expression in a sequence specific 
manner [66]. Plasmid DNA can be used to deliver siRNA or short hairpin RNA, which is 
digested by dicer, a member of the RNase III family of enzymes, to siRNA [67]. 
 In addition to the function as a provider of information about RNA or protein, DNA, 
especially short ones, exhibit a variety of biological functions in the form of DNA. For 
example, single stranded DNA can bind specifically to another DNA or RNA strand of a 
complementary sequence, and interferes with the function of the DNA/RNA. Organisms use 
the interaction of DNA with proteins in many biological processes, such as the regulation of 
gene expression, which is controlled by the binding of transcription factors (proteins) to their 
binding sites in the genome DNA. Such interactions can be modulated by DNA with suitable 
characteristics administered externally [27]. 
 Various types of DNA and related molecules, such as chemically modified DNA, RNA 
and their hybrids, have been developed as candidates for pharmaceutical agents. The 
categories of nucleic acid drugs include: antisense DNA, ribozyme, decoy ODN, aptamer, 
CpG DNA and small interfering RNA (siRNA) [51,68]. These compounds exhibit their 
pharmacological activity by interacting with their target molecules. Antisense DNA is 
designed to bind to complementary RNA, so that the action of the protein translated from the 
RNA can be blocked. Ribozyme is an RNA enzyme that catalyzes specific cleavage of RNA 
molecules, and several modifications of the structure, such as DNA-RNA chimera, have been 
considered to increase the stability. siRNA is another, and the most recent, compound that can 
degrade target mRNA through the interaction with RNA inducible silencing complex. 
 Decoy ODN, a short double stranded DNA, is a “decoy” for transcription factors, such 
as nuclear factor-B, and blocks the signaling through the transcription factor of interest [69]. 
In general, transcription factor binding motifs are <10 base pairs, so that double stranded 
DNA with about 20 base pairs are used as decoy DNA. When DNA binds to proteins other 
than transcription factors and modulates their functions, it is called an aptamer. DNA, RNA, 
chemically modified nucleic acids or their hybrids ranging from 20 to hundreds of bases in 
length have been examined for application as aptamers [70]. 
 
4. DNA-mediated stimulation of innate immunity 
4.1. Immunostimulatory activity of extracellular/cytosolic DNA 
DNA, which is stored in the nucleus and mitochondria in live cells, is released outside cells 
when cells are dying or dead. These DNA contain phosphodiester bonds, so that DNA 
degrading enzymes degrade the released DNA into small pieces. In addition to the enzymatic 
degradation, some cells, such as macrophages and liver sinusoidal endothelial cells, have an 
ability to take up extracellular DNA through mechanisms recognizing polyanions, and break it 
down by DNA degrading enzymes in the lysosomes [71-73]. Thus, DNA outside cells is 
quickly cleared or degraded by various endogenous mechanisms, and its concentration is kept 
very low [74-78]. When the homeostasis is impaired and the concentration of DNA in the 
cytosol or extracellular space is increased, DNA can be recognized as a danger signal [79,80]. 
The amount of extracellular DNA increases in various pathophysiological conditions, 
including cancer, rheumatoid arthritis and other autoimmune diseases [81-84]. Recently, the 
binding of an antimicrobial peptide LL37 to self-DNA has been shown to convert the inert 
DNA into a potent trigger of interferon production [85]. These pieces of evidence clearly 
indicate that DNA is a bioactive compound once its instability in biological fluids is modified 
or prevented. 
 
4.2. CpG DNA as a signal of infection 
It is potentially very dangerous if an individual is invaded by foreign pathogens, such as 
bacteria and viruses. To sense such invasions, the innate immune system of mammals uses 
Toll-like receptors (TLRs), a family of highly conserved pattern-recognizing receptors for 
self-defense [86]. TLRs recognize the unique structures of invaders, which include 
lipopolysaccharide, a component of the outer membrane of Gram-negative bacteria, 
peptidoglycan, a component of bacterial cell wall, and double stranded RNA, a component of 
RNA viruses. Each type of TLR has been evolved to detect one or more of these structures 
unique to, or abundant in, microbes. Although both mammals and microbes use DNA to 
transmit genetic information, there are some differences in the characteristics of the DNA. 
One very important difference between mammalian DNA and bacterial/viral DNA is that the 
C5 position of cytosine in CG dinucleotides in mammalian DNA is highly methylated [87]. In 
addition, the frequency of CG dinucleotides in mammalian DNA is much lower than the 
expected frequency of 1 out of 16. These characteristics provide mammalian DNA with very 
few unmethylated CG dinucleotides (CpG motifs). This is not the case for bacterial and viral 
DNA, both of which contain unmethylated CG dinucleotides at a frequency close to the 
expected value. Therefore, the difference in the frequency of CpG motifs in DNA is used to 
sense the invasion of foreign microbes, and TLR9 is the receptor for the CpG motif. This 
sensing activates the innate immune system and proinflammatory cytokines are released from 
the TLR9-positive cells, such as dendritic cells. 
 
4.3. Therapeutic applications of CpG DNA 
Because of its ability to boost the innate immune response to cancer cells or virally infected 
cells, CpG DNA in various forms has been developed and used in preclinical and clinical 
trials [88]. The forms of CpG DNA developed thus far include short single stranded 
phosphorothioate DNA of several tens of bases, CpG-replete plasmid DNA, and their 
complex with cationic compounds. CpG DNA stimulates the production of Th1-type 
cytokines, including interleukin (IL)-12 and interferon (IFN)-, both of which have been 
shown to exhibit antitumor activity against a variety of tumors [89,90]. In addition, it can be 
considered to be effective in correcting the Th1/Th2 imbalance observed in a variety of 
allergic diseases.  
 
5. DNA assemblies with designed architecture 
5.1. General characteristics of DNA assemblies 
DNA molecules of a small size are generally designed in a single- or double stranded form 
with a proper length, depending on the requirements for each category of nucleic acid drugs. 
These DNA drugs can be incorporated as a part of large DNA-based systems, or can be 
delivered using such systems, although such trials are in their infancy. 
 Recent major advances in developing nano-sized assemblies of DNA molecules have 
opened up new frontiers for the use of DNA as a building block of nano-sized materials with 
precisely designed architectures. Various methods have been reported and unique structures, 
such as DNA dendrimer [14], DNA barcode [91], DNA polyhedron [18] and DNA hydrogel 
[15], have appeared for the first time in the last decade (Figure 1). These 3-dimentional 
structures of DNA are constructed using the property of DNA to form duplexes with 
complementary strands. Some of these nano-sized DNA assemblies have been used in 
biomedical applications. 
 It is not yet well understood how DNA assemblies are recognized by the body, because 
such a structure cannot be found in nature. Even though the components are natural DNA, the 
overall structure of DNA assemblies may be handled in a different manner from that of simple 
single stranded- or double stranded DNA in linear or circular form. On the other hand, most 
DNA assemblies developed thus far are constructed using single stranded DNA with 
phosphodiester linkages of varying lengths. In addition, most of the assemblies consist of 
double stranded DNA. Therefore, the component parts of the DNA assemblies are exactly the 
same as natural DNA molecules, such as genome, bacterial and plasmid DNA, so that the 
body may not distinguish between them. In the following section, we briefly summarize our 
recent findings, which have clearly shown that Y-shaped DNA, a very simple type of DNA 
assembly, is recognized by TLR9-positive cells in a different manner from the natural form of 
straight (I-shaped) single- or double stranded DNA. 
 
5.2. Increased immunostimulatory activity of DNA by Y-shape formation 
One of the basic structures of DNA units for constructing DNA assemblies is a branched 
double stranded DNA, such as T-, X-, and Y-shaped DNA. These branched double stranded 
DNA molecules can be formed using three (for T- and Y-DNA) or four (X-DNA) ODNs with 
the halves of each ODN being partially complementary to half of the other two ODNs (Figure 
3a). The Y-DNA has three double stranded DNA sequences, all of which are connected in the 
center of the structure. Therefore, the structural properties of Y-DNA are similar to those of 
double stranded DNA, except for the presence of a 3-way junction in the middle of the 
structure. Our previous study using several preparations of Y-DNA showed that (i) Y-DNA 
induced greater amounts of proinflammatory cytokines from RAW264.7 macrophage-like 
cells than double stranded DNA; and (2) greater amounts of Y-DNA were taken up by 
macrophage-like cells compared with double stranded DNA [92]. Figure 3b summarizes the 
tumor necrosis factor (TNF)- concentration in the culture media of RAW264.7 cells that 
were mixed with several types of DNA molecules. As clearly demonstrated in this figure, the 
Y-shape formation was effective in increasing the immunostimulatory activity of DNA 
irrespective of the presence of CpG motifs in the DNA molecules. In addition, we found that 
the Y-DNA was not as stable as double stranded DNA. Preliminary studies using 
dendrimer-like DNA, which was constructed using several Y-DNA preparations as reported 
previously [14], showed that highly structured DNA assemblies are more potent 
immunostimulatory compounds than double stranded DNA [93]. Increased uptake of these 
DNA assemblies could be explained by experimental data showing that a longer DNA is more 
efficiently taken up by cells than a shorter one [94]. Further studies are required to determine 
the exact mechanism of the increased immunostimulatory activity of branched DNA 
preparations. 
 
6. Conclusions and future perspectives  
Technological advances have allowed us to modify DNA to become a bioinert or 
immunostimulatory compound with varying length and varying stability. The recent explosive 
expansion of knowledge about how to design and develop DNA assemblies will further 
increase the possibilities for the pharmaceutical and biomedical application of DNA 
molecules. Nano-sized compounds, such as liposomes, nanoparticles, macromolecular 
micelles and viruses, are useful for delivering pharmaceutical agents to specified sites, 
including solid tumors, and DNA-based nano-sized systems can also be used as a targeting 
vehicle for such sites. In addition, DNA can be a carrier for anthracyclines as demonstrated in 
the pioneer work of Trouet et al [95]. Therefore, DNA-based nano-sized systems consisting of 
DNA assemblies are a novel class of delivery systems for a wide variety of bioactive agents. 
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FIGURE LEGENDS 
Fig. 1. Schematic presentation of a variety of DNA assemblies. In most cases, double 
strand formation between two DNA molecules is the driving force to form DNA assemblies. 
(a) Y-DNA, (b) X-DNA, (c) dendrimaer-like DNA (Y-DNA based), (d) DNA tetrahedron, and 
(e) DNA dodecahedron. Each line represents one (a-c) or more (d,e) DNA strands. 
 
Fig. 2. Structures of natural (phosphodiester) DNA and several DNA derivatives. Most 
DNA derivatives are more resistant to degradation by DNases than phosphodiesters. (a) 
phosphodiester DNA, (b) phosphothioate DNA, (c) methylphosphonate DNA, (d) 
2‟-O-methyl RNA (X=O or S), (e) locked nucleic acid, (f) morpholino and (g) PNA. 
 
Fig.3. Increased immunostimulatory activity of DNA by Y-shape formation. (a) The 
sequence and putative structure of the preparations of Y-DNA. (b) Concentrations of TNF- 
in culture media of RAW264.7 cells mixed with each type of DNA. (Closed bars) TNF-, 
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